Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAMAVOC
NCT07826988Phase 4Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2026
- Primary completion
- Oct 2029
01
Overview
Phase 4, randomised trial of ketamine, nefopam, tramadol and ketoprofen in vaso-occlusive crisis (VOC) (8 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Time to resolution of vaso-occlusive crisis at 14 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ketaminenefopamtramadolketoprofen
03
Conditions
vaso-occlusive crisis (VOC)
Beyond the preview
Go deeper on NCT07826988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07826988.